Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Unicycive Therapeutics, Inc. (UNCY)

0.56   -0.043 (-7.05%) 01-27 16:00
Open: 0.59 Pre. Close: 0.6025
High: 0.6124 Low: 0.5421
Volume: 67,968 Market Cap: 8(M)

Technical analysis

as of: 2023-01-27 4:48:51 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.78     One year: 0.97
Support: Support1: 0.4    Support2: 0.33
Resistance: Resistance1: 0.67    Resistance2: 0.83
Pivot: 0.54
Moving Average: MA(5): 0.59     MA(20): 0.53
MA(100): 0.64     MA(250): 0.85
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 86.9     %D(3): 93
RSI: RSI(14): 46.7
52-week: High: 1.63  Low: 0.4
Average Vol(K): 3-Month: 283 (K)  10-Days: 122 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ UNCY ] has closed below upper band by 42.4%. Bollinger Bands are 21.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.61 - 0.62 0.62 - 0.62
Low: 0.53 - 0.54 0.54 - 0.54
Close: 0.55 - 0.56 0.56 - 0.57

Company Description

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Headline News

Thu, 26 Jan 2023
Our Exclusive Articles - Benzinga

Mon, 23 Jan 2023
2023-01-23 | NDAQ:UNCY | Press Release | Unicycive Therapeutics ... - Stockhouse

Thu, 05 Jan 2023
Unicycive Announces Acceptance of Four Abstracts for Presentation ... - Yahoo Finance

Wed, 28 Dec 2022
Is Unicycive Therapeutics Inc (UNCY) Stock a Good Value Wednesday? - InvestorsObserver

Wed, 28 Dec 2022
UNCY stock jumps as kidney disease drug meets main goal in key ... - Seeking Alpha

Mon, 21 Nov 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 15 (M)
% Held by Insiders 4.89e+006 (%)
% Held by Institutions 41.3 (%)
Shares Short 54 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 627.6
Return on Equity (ttm) -64.6
Qtrly Rev. Growth 951000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 67370
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.